Fri, 23rd Oct 2020 19:39
(Recasts with confirmation)
Oct 23 (Reuters) - AstraZeneca Plc has resumed the
U.S. trial of its experimental COVID-19 vaccine after approval
by U.S. regulators, the company said on Friday.
AstraZeneca's U.S. trial was paused on Sept. 6 after
a report of a serious neurological illness, believed to be
transverse myelitis, in a participant in the company's UK trial.
(Reporting by Munsif Vengattil and Carl O'Donnell; Editing by
Anil D'Silva and Rosalba O'Brien)
April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...
(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe a...
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', ...
Astrazeneca (AZN)